Cidara Therapeutics, Inc. CDTX Cash Flow

Cidara therapeutics, inc. (CDTX)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14
Operating activities:
Operating activities:
Net Income (Loss) Attributable to Parent
-39,070	-41,092	-39,411	-56,069	-58,828	-59,016	-60,102	-58,740	-59,079	-55,728	-56,694	-56,664	-51,774	-48,165	-43,639	-40,586	-35,245	-32,193	-26,974	-21,119	-17,924	-11,894	0	0	0
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
285	300	362	418	470	523	551	558	608	667	713	747	751	732	719	641	549	461	0	0	0	-	-	-	-
Stock-based compensation
5,035	5,073	5,414	5,190	5,533	5,710	5,854	6,123	6,124	5,714	5,296	5,054	4,562	4,344	4,042	3,496	3,227	3,033	2,420	1,703	869	232	0	0	0
Amortization of debt issuance costs and debt discount
-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash interest expense
22	28	65	20	35	43	0	0	0	-	-	-	-	-	-	-	0	-	-	-	-	66	0	0	0
Amortization of discount or premium on short-term investments
-	-	-	-	-	-31	-48	-67	-42	33	94	143	178	176	0	0	0	-	-	-	-	-	-	-	-
Change in fair value of convertible notes payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-183	0	0	0
Amortization of debt issuance costs
6	8	-27	17	10	13	0	0	0	-	-	-	-	-	-	-	-	22	17	11	19	23	0	0	0
Operating lease right-of-use assets and liabilities, net
-37	47	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred rent
-	-	-	-	-	-30	-1	28	34	29	23	19	14	8	4	-62	-59	-54	0	0	0	-	-	-	-
Change in fair value of contingent forward purchase obligations
681	411	4,486	5,374	3,581	3,851	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Changes in assets and liabilities:
Accounts receivable, prepaid expenses, other current assets, and other assets
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable and accrued liabilities
826	-784	1,178	157	-1,839	-59	860	-3,067	1,990	642	-879	4,974	2,813	1,913	3,212	1,478	406	2,143	1,637	723	1,628	1,746	0	0	0
Accrued compensation and benefits
596	1,244	753	789	698	822	1,213	1,047	932	453	316	677	850	1,760	1,424	1,144	872	1,050	861	729	358	414	0	0	0
Prepaid expenses and other current assets
-	-	-	-	-	211	2,181	1,405	583	1,481	522	434	337	76	270	406	598	487	735	641	224	204	0	0	0
Deferred revenue
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Investing activities:
Net cash used in operating activities
-	-	-	-	-	-	-	0	0	-	-	0	-43,403	-	-34,783	-34,399	-30,793	-25,959	-22,393	-18,314	-13,352	-7,710	0	0	0
Investing activities:
Purchases of short-term investments
-	-	-	-	-	14,548	24,191	34,071	25,326	19,523	9,880	21,835	59,658	69,617	0	0	0	-	-	-	-	-	-	-	-
Maturities of short-term investments
-	-	-	-	-	29,026	29,526	19,756	19,185	24,300	54,800	79,800	96,900	95,500	0	0	0	-	-	-	-	-	-	-	-
Purchases of property and equipment
62	35	75	157	155	177	277	186	221	306	280	359	463	401	749	1,230	1,193	1,170	854	470	1,021	991	0	0	0
Net cash used in investing activities
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Financing activities:
Net cash (used in) provided by investing activities
-	-	-	-	-	-	-	0	0	-	-	0	36,779	-	-5,346	-58,930	-46,070	-46,088	-50,792	-470	-1,021	-991	0	0	0
Financing activities:
Proceeds from issuance of common and preferred stock pursuant to rights offering, net of issuance costs
29,186	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of common stock, net of issuance costs
0	-	-	0	0	-	-	0	27,175	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of convertible notes payable, net of offering costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	930	0	0	0
Deferred initial public offering costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Proceeds from exercise of stock options
12	7	0	165	176	204	280	118	112	228	607	608	628	525	341	337	312	387	855	847	855	749	0	0	0
Repurchase of unvested restricted stock
-	-	-	-	-	-	-	-	-	79	79	79	79	0	0	0	0	-	-	-	-	-	-	-	-
Net cash provided by financing activities
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by financing activities
-	-	-	-	-	-	-	0	0	-	-	0	37,118	-	280	299	70,443	111,813	112,088	112,078	71,783	31,312	0	0	0
Net increase (decrease) in cash, cash equivalents, and restricted cash
16,907	-14,294	-9,956	-44,381	4,397	13,749	0	0	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Net increase (decrease) in cash and cash equivalents
-	-	-	-	-	-	-	-	-	-	-	-	-	22,805	-39,849	-93,030	-6,420	39,766	38,903	93,294	57,410	22,611	0	0	0
Supplemental disclosure of cash flows:
Interest paid
600	616	622	615	600	582	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest paid
-	-	-	-	-	-	-	-	-	-	-	0	118	-	0	0	0	-	-	-	-	-	-	-	-
Non-cash investing activities:
Right-of-use asset obtained in exchange for lease liability
0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Property and equipment acquired but not yet paid
-	-	-	-	-	-	-	-	-	-	-	-	-	21	0	0	0	-	-	-	0	-	-	-	-
Non-cash financing activities:
Deferred initial public offering costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-
Vesting of early exercised stock options
-	-	-	-	-	21	30	37	37	44	66	87	138	197	0	0	0	-	-	-	-	-	-	-	-
Deferred financing costs incurred but not yet paid
-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-